Table 5.

Response to a change in the AFT used in patients who had progression of the IA after transplantation

	No. patients treated as salvage AFT*	No. patients who responded to salvage AFT (%)
Salvage AFT given for IA after allo-HSCT
Azoles (itraconazole/voriconazole)	12 (8/4)	3 (25)
AmB formulations (c-AmB/ABLC/L-AmB)	9 (2/3/4)	3 (33)
Caspofungin	4	2 (50)
No salvage AFT	10	1 (10)†
All patients at risk	27‡	6 (22)

AmB indicates amphotericin B; and ABLC, AmB lipid complex.

^*Salvage antifungal therapy used after progression of IA after HSCT.

^†One patient was not given salvage AFT for progression of IA because his leukemia recurred shortly thereafter. Nevertheless, IA decreased more than 50% within 3 weeks.

^‡In 8 (30%) of 27 patients, more than 1 drug was used in combination.